KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study

BMC Cancer

Jasmina-Ziva Cerne¹  Vida Stegel²  Ksenija Gersak¹  Srdjan Novakovic² 

[1] Institute of Medical Genetics, Department of Obstetrics and Gynecology, University Medical Center Ljubljana, Slajmerjeva 3, Ljubljana 1000, Slovenia

[2] Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Zaloska 2, Ljubljana 1000, Slovenia

关键词: Hormone replacement therapy;    Tumor characteristics;    Breast cancer;    KRAS rs61764370;   

Others  :  1080502
DOI  :  10.1186/1471-2407-12-105

 received in 2011-11-07, accepted in 2012-03-22,  发布年份 2012

【 摘 要 】

Background

A single nucleotide polymorphism located in the 3'-untranslated region of the KRAS oncogene (KRAS variant; rs61764370) disrupts a let-7 miRNA binding and was recently reported to act as a genetic marker for increased risk of developing human cancers. We aimed to investigate an association of the KRAS variant with sporadic and familial breast cancer and breast tumor characteristics.

Methods

Genotyping was accomplished in 530 sporadic postmenopausal breast cancer cases, 165 familial breast cancer cases (including N = 29, who test positive for BRCA1/2 mutations) and 270 postmenopausal control women using the flurogenic 5' nuclease assay. Information on hormone replacement therapy (HRT) use and tumor characteristics in sporadic breast cancer cases was ascertained from a postal questionnaire and pathology reports, respectively. Associations between the KRAS genotype and breast cancer or breast tumor characteristics were assessed using chi-square test and logistic regression models.

Results

No evidence of association was observed between the KRAS variant and risk of sporadic and familial breast cancer - either among BRCA carriers or non-BRCA carriers. The KRAS variant was statistically significantly more often associated with human epidermal growth factor receptor 2 (HER2) - positive tumors and tumors of higher histopathologic grade. However, both associations were detected only in HRT users.

Conclusion

Our data do not support the hypothesis that the KRAS variant rs61764370 is implicated in the aetiology of sporadic or of familial breast cancer. In postmenopausal women using HRT, the KRAS variant might lead to HER2 overexpressed and poorly-differentiated breast tumors, both indicators of a worse prognosis.

【 授权许可】

   
2012 Cerne et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
• [2]Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
• [3]Kent OA, Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25:6188-6196.
• [4]Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al.: RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
• [5]Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al.: A SNP in a let-7 microRNA complementary site in the KRAS 3' UTR increases non-small cell cancer risk. Cancer Res 2008, 68:8535-8540.
• [6]Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al.: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753-3756.
• [7]Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, et al.: A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009, 30:1003-1007.
• [8]Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, et al.: A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 2010, 70:6509-6515.
• [9]Pharoah PDP, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, et al.: The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011, 17:3742-3750.
• [10]Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, et al.: Prevalence of the variant allele rs61764370 T > G in the 3' UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat 2011, 128:79-84.
• [11]Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, et al.: A 3'- untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 2011, 12:377-386.
• [12]Cerne JZ, Gersak K, Novakovic S: The influence of the genetic variant within miRNA-binding site in estrogen receptor alpha gene on the risk of breast cancer in postmenopausal women on hormone replacement therapy. Cancer Biomark 2011, 8:123-128.
• [13]Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
• [14]Kumar MS, Swanton C: KRAS 3'-UTR variants and stratification of breast-cancer risk. Lancet Oncol 2011, 12:318-319.
• [15]Cerne JZ, Frkovic-Grazio S, Gersak K: Breast tumor characteristics in hormone replacement therapy users. Pathol Oncol Res 2011, 17:917-923.
• [16]Nicholson RI, McClelland RA, Robertson JFR, Gee JMW: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999, 6:373-387.
• [17]Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, et al.: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002, 80:239-256.
• [18]Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR, et al.: Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat 2011, 127:69-80.